5Venditti M, Monaco M, Micozzi A, et al. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies [ J ]. Clin Microbiol Infect, 2001,7 (1) :37 -39.
6Tatman-Otkun M, Gurcan S, Ozer B, et al. The antimicrobial susceptibility of Stenotrephomonas maltophilia isolates using three different methods and their genetic relatedness[ J]. BMC Microbiology,2005, 5(1) :24 -29.
二级参考文献9
1National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
2Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
3Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
4Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
5Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.
